Personalized medicine in multiple sclerosis: Hope or reality?

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Derfuss, Tobias ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarker; Multiple Sclerosis; Personalized Medicine

Indexed keywords

AQUAPORIN 4 ANTIBODY; BETA INTERFERON; BIOLOGICAL MARKER; CD56 ANTIGEN; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; NATALIZUMAB; NEUTRALIZING ANTIBODY; OLIGOCLONAL BAND; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

CEREBROSPINAL FLUID; COST BENEFIT ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; GENETIC MARKER; GENETICS; IMMUNE RESPONSE; JC VIRUS; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT SURVEY; TRANSCRIPTOMICS; TREATMENT INDICATION;

BIOLOGICAL MARKERS; CLINICAL MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 84866912534     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-116     Document Type: Short Survey

References (35)

1. Skoog B, Runmarker B, Winblad S, Ekholm S, Andersen O. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain 2012, 135:900-911. 10.1093/brain/awr336, 22366800.
2. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993, 116(Pt 1):117-134.
3. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782. 10.1093/brain/awg081, 12615637.
4. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989, 112(Pt 6):1419-1428.
5. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006, 129:584-594. 10.1093/brain/awh721, 16401620.
6. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010, 133:1914-1929. 10.1093/brain/awq118, 2892939, 20534650.
7. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817. 10.1093/brain/awm329, 18234696.
8. Schlaeger R, D'Souza M, Schindler C, Grize L, Dellas S, Radue EW, Kappos L, Fuhr P. Prediction of long-term disability in multiple sclerosis. Mult Scler 2012, 18:31-38. 10.1177/1352458511416836, 21868486.
9. Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porque P, Villarrubia N, Espino M, Garcia-Trujillo JA, Bootello A, Alvarez-Cermeno JC. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115:187-194. 539201, 15630459.
10. Tintore M, Rovira A, Arrambide G, Mitjana R, Rio J, Auger C, Nos C, Edo MC, Castillo J, Horga A, Perez-Miralles F, Huerga E, Comabella M, Sastre-Garriga J, Montalban X. Brainstem lesions in clinically isolated syndromes. Neurology 2010, 75:1933-1938. 10.1212/WNL.0b013e3181feb26f, 21098409.
11. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, Inglese M, Guttmann CR, Horsfield MA, Filippi M. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008, 7:615-625. 10.1016/S1474-4422(08)70137-6, 2586926, 18565455.
12. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008, 64:247-254. 10.1002/ana.21423, 18570297.
13. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009, 5:553-560. 10.1038/nrneurol.2009.139, 19794514.
14. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010, 9:740-750. 10.1016/S1474-4422(10)70103-4, 20610349.
15. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009, 23:379-396. 10.2165/00023210-200923050-00003, 19453200.
16. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, Julia E, Fernandez M, Nonell L, Camina-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365. 10.1093/brain/awp228, 19741051.
17. Derfuss T, Meinl E. Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?. Curr Opin Neurol 2012, 25:231-238. 10.1097/WCO.0b013e3283533a64, 22487571.
18. Hinson SR, McKeon A, Lennon VA. Neurological autoimmunity targeting aquaporin-4. Neuroscience 2010, 168:1009-1018. 10.1016/j.neuroscience.2009.08.032, 19699271.
19. Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, Villalobos A, Breithaupt C, Weissert R, Jacob U, Krumbholz M, Kuempfel T, Blaschek A, Stark W, Gärtner J, Pohl D, Rostasy K, Weber F, Forne I, Khademi M, Olsson T, Brilot F, Tantsis E, Dale RC, Wekerle H, Hohlfeld R, Banwell B, Bar-Or A, Meinl E, Derfuss T. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011, 77:580-588. 10.1212/WNL.0b013e318228c0b1, 21795651.
20. Lalive PH, Hausler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011, 17:297-302. 10.1177/1352458510389220, 21177754.
21. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012, 367:115-123. 10.1056/NEJMoa1110740, 22784115.
22. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006, 103:5941-5946. 10.1073/pnas.0601335103, 1458677, 16585503.
23. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010, 9:381-390. 10.1016/S1474-4422(10)70033-8, 20163990, CHOICE investigators.
24. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744, AFFIRM Investigators.
25. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366:1870-1880. 10.1056/NEJMoa1107829, 22591293.
26. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303. 10.1002/ana.22128, 20737510.
27. Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011, 77:573-579. 10.1212/WNL.0b013e318228bec5, 21795656.
28. Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009, 119:2052-2061. 2701868, 19546505.
29. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JJ, Su YH, Lan SH, Sung SF, Lin SY, Chuang HP, Huang LC, Chen YJ, Tsai PJ, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011, 364:1126-1133. 10.1056/NEJMoa1009717, 21428768.
30. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, et al. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. 10.1038/nature10251, 3182531, 21833088, International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2.
31. De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P, Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler DA, Karlson EW. Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009, 8:1111-1119. 10.1016/S1474-4422(09)70275-3, 3099419, 19879194, Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study.
32. Oksenberg J, Hauser SL. Genetics of multiple sclerosis. Multiple Sclerosis 2008, 214-225. London: Saunders Elsevier, Raine CS, McFarland H, Hohlfeld R.
33. Comabella M, Vandenbroeck K. Pharmacogenomics and multiple sclerosis: moving toward individualized medicine. Curr Neurol Neurosci Rep 2011, 11:484-491. 10.1007/s11910-011-0211-1, 21701907.
34. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
35. Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, Poschmann G, Kaur G, Lambert L, Leach OA, Prömel S, Punwani D, Felce JH, Davis SJ, Gold R, Nielsen FC, Siegel RM, Mann M, Bell JI, McVean G, Fugger L. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488:508-511. 10.1038/nature11307, 22801493.